Merck Frosst Canada, Inc.

Merck + Co., Inc.

Simon Fraser University

Merck Frosst Canada & Co.

Other

Ossifi Therapeutics LLC

Merck Sharp + Dohme Corp.

The University of British Columbia

Osteoqc, Inc.

Merck Frosst Company

Robert N Young

Robert J Zamboni

Joshua Rokach

Yongxin Han

Patrice C Belanger

Richard Frenette

Claude Dufresne

Masatoshi Kakushima

Debra Ellies

F Scott Kimball

Jacques-Yves Gauthier

Yves Leblanc

John Colucci

Marie-Claire Wilson

Xavier Billot

Yves Girard

Yvan Guindon

Jacques Yves Gauthier

Serge Leger

Haydn W Williams

Michel L Belley

Gideon A Rodan

John Scheigetz

Gang Chen

John Howard Hutchinson

Cheuk K Lau

Michel Therien

John W Gillard

Yves Ducharme

Petpiboon Prasit

Marc Labelle

Kathleen M Metters

Paul Rennie

Shun-ichi Harada

Andre Giroux

Artem Tcherkassov

Laird A Trimble

Deborah A Nicoll-Griffith

James A Yergey

Marion Thévenin

Helene Perrier

Christophe M Andre

Edward C Hayes

Haydn R Williams

Zhaoyin Wang

Peter Charles Tyler

Thomas R Verhoeven

Daniel Dube

Joseph G Atkinson

Richard W Friesen

Patrick Roy

Claudio F Sturino

Christopher I Bayly

Marc Blouin

Carl Berthelette

Lianhai Li

Yves Gareau

Rejean Ruel

Yi Bin Xiang

Mohammed Monzur Morshed

Sylvie Desmarais

Troy Mark Gonsalves

Geoffrey Vanderkooy

Rick Friesen

Stephen Paul Arns

John Schiegetz

Maryann Fitzsimmons, Heir

Marc LaBelle

Nicholas Lachance

Brian Fitzsimmons, Deceased

Dwight Mac Donald

Carole Lepine

Dwight MacDonald

Laurent Gil

Mohamed Machwate

Mohamed MacHwate

Philip Thomas

Romelo Gibe

Anne Moreau

Haibo Xie

Stephen Arns

Monzur Morshad

In one aspect, the invention provides compounds of Formula I, and salts, hydrates and isomers thereof. In another aspect, the invention provides a method of promoting bone formation in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of Formula I. The present invention also provides orthopedic and periodontal devices, as well as methods for the treatment of renal disease, diabetes, bone loss, and cancer, using a compound of Formula I.

Fluoro beta-carboline compounds

In one aspect, the invention provides compounds of Formula I Formula Ia, Formula Ib, Formula Ic, and Formula Id and salts, hydrates and isomers thereof. In another aspect, the invention provides a method of promoting bone formation in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of Formula I, Formula Ia, Formula Ib, Formula Ic, or Formula Id. The present invention also provides orthopedic and periodontal devices, as well as methods for the treatment of renal disease, diabetes bone loss, and cancer, using a compound of Formula I, Formula Ia, Formula Ib, Formula Ic, or Formula Id.

Pyrrolo-dipyridine compounds

In one aspect, the invention provides compounds of Formula I Formula Ia, Formula Ib, Formula Ic, and Formula Id and salts, hydrates and isomers thereof. In another aspect, the invention provides a method of promoting bone formation in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of Formula I, Formula Ia, Formula Ib, Formula Ic, or Formula Id. The present invention also provides orthopedic and periodontal devices, as well as methods for the treatment of renal disease, diabetes bone loss, and cancer, using a compound of Formula I, Formula Ia, Formula Ib, Formula Ic, or Formula Id. 

The present invention relates to EP4 agonist-bisphosphonate conjugates or related compounds and uses thereof. Said conjugates or related compounds may be used to provide delivery of an EP4 agonist or related compound to a desired site of action, such as a bone. Bisphosphonate moieties, linked to the EP4 agonists via amide linkers, have been implicated in the inhibition of bone resorption and bone targeting.

Amide-linked EP4 agonist-bisphosphonate compounds and uses thereof

This invention provides compound having a structure of Formulas:  Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provide.

Binding Function 3 (BF3) site compounds as therapeutics and methods for their use

The present invention relates to conjugate compounds and methods of making and using same.

This invention provides compound having a structure of Formulas: Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provide. 

[object Object]

The invention provides in part, compounds according to Formula I: and uses thereof.

Dual-action EP4 agonist&#x2014;bisphosphonate conjugates and uses thereof

The invention provides in part, conjugate compounds. The invention also provides synthesis methods for making the compounds, and uses of the compounds.

Prostaglandin-bisphosphonate conjugate compounds, methods of making same, and uses thereof

An automatic alarm system is described that is triggered by the lack of event at one or more portable remote unit(s). The system includes an electromagnetic interface from a plurality of portable units to a central command and monitoring element. This automatic triggering of an alarm condition adds security to the users of the system since it is not always feasible to explicitly trigger an alarm when in danger.

Security system with automatic alarm

This invention relates to potent selective agonists of the EPsubtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions, which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts.

EPreceptor agonist, compositions and methods thereof

The invention encompasses novel compounds of Formula I, which are nitric oxide-releasing prodrugs of diaryl-2-(5H) furanones useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions and methods for treatment of cyclooxygenase-2 mediated diseases comprising the use of compounds of Formula I. The above compounds may be used as a combination therapy with low-dose aspirin to treat chronic cyclooxygenase-2 mediated diseases or conditions while simultaneously reducing the risk of thrombotic cardiovascular events 

Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors

Growing community of inventors

Senneville, Canada

Robert N Young